The WHO/ATC (Anatomical Therapeutic Chemical) index DDD (WHO-DDD) is commonly used for drug consumption measurement. Discrepancies between WHO-DDD and actual prescribed daily doses (PDD) in hospitals have prompted alternative dose definitions adapted to doses recommended in hospital practice guidelines [recommended daily doses (RDD)].
Introduction
Appropriate use of antibiotics is decisive in minimizing antibacterial resistance, and there is little doubt that healthcare institutions need to monitor and feedback data on antibiotic consumption to prescribers in order to identify areas for improved prescription quality. [1] [2] [3] There has been controversy about which metrics of antimicrobial drug use measurement in the different healthcare settings are best for benchmarking and research purposes. [4] [5] [6] [7] [8] [9] [10] [11] [12] A relatively accurate measure is the enumeration of days of treatment (DOT) or actual prescriptions of a given drug in the individual patient. 13 Although such patient-level analyses have many advantages they are unfortunately often unavailable. Alternatively, V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. many hospitals can easily provide aggregate antibiotic consumption data in the form of recalculated standardized doses of dispensed drugs per hospital bed, admission or patient-day. For this consumption indicator, the most common methodology has been to calculate the drug volume as the value of the WHO/ATC (Anatomical Therapeutic Chemical) index DDD (WHO-DDD) according to current versions of the WHO/ATC index and represent it as DDD per 100 patient-days as denominator. This indicator of drug use density can be applied across health systems and is often used for benchmark purposes. A disadvantage of this indicator may be that WHO-DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults with a moderately severe infection and has not specifically been defined for hospital settings. WHO-DDD often differ from and are lower than actual prescribed daily doses (PDD) in the hospital. Thus, calculating antibiotic use density with WHO-DDD as numerator can lead to an overestimation of antibiotic exposures when compared with DOT or factual PDD. 6, 11, 14, 15 Hospital-adapted dose definitions have also been used to estimate antibiotic use density, but few studies have prospectively compared the overall as well as drug class-specific differences between WHO-DDD, PDD/DOT and adapted dose definitions. 8, 14, 16 We have used a set of hospital practice guideline adapted dose definitions for cross-sectional antibiotic use density evaluation in Germany. These adapted dose definitions [specifying guideline-'recommended daily doses' (RDD); see Table S1 , available as Supplementary data at JAC Online], however, have been validated only by means of single-centre point prevalence surveys (PPS) performed in a university hospital. 6 The present study sought to validate RDD definitions as applied in a current German hospital antibiotic use surveillance system using a multicentre approach including community hospitals.
Methods

Study design
The present study used data obtained during PPS conducted in 24 German acute care hospitals in the years 2013-15. The hospitals were located in different regions and included 5 university hospitals and 19 other acute care hospitals of varying size (,400 beds, 8; 400-800 beds, 6; .800 beds, 5). The PPS were performed twice in each hospital (with at least 6 months between surveys) and modified so that antibiotic prescription data were not only retrieved for the day of the survey (D0), but for patients included in the PPS we also recorded antibiotic prescriptions documented for the 6 days immediately preceding the day of the survey (D-6-1). This modification was made in order to enlarge the database and include rarely prescribed substances.
We included all adult (at least 18 years of age) inpatients on the days of the PPS and screened them for prescription of systemic antimicrobial drugs through chart review by a trained medical doctor or pharmacist. Training in conducting surveys had been obtained during participation of the responsible healthcare workers in specialized hospital antibiotic stewardship courses (www.antibiotic-stewardship.de). Participants were asked to include in the survey all core services of their hospital including medicine and surgery, but to exclude psychiatry and psychosomatics. Patients with antimicrobial drugs prescribed on the day of the survey were assessed regarding demographic data, systemic antimicrobial drugs on D0 and D-6-1 with indication (therapy, prophylaxis, unknown), dose and administration, renal function (using estimated glomerular filtration rate) and diagnosis of infection (clinical diagnosis and pathogen if known) if any. The information was entered online into a database and centrally checked for plausibility, accuracy and completeness. The study included on-site monitoring and source data verification by a trained study nurse for 20% of randomly selected cases. All data were subjected to a plausibility reassessment by a clinical pharmacist. Additionally, an infectious disease specialist checked the interrater reliability for 5% of all cases. Attempts were made to resolve all queries resulting from checking key data and case monitoring before eventual closing of the database and final analysis.
Dose definitions
PDD were defined as any systemic antibacterial drug prescribed on the day of (or in the preceding 6 days prior to the day of) the survey independent of the dose given and corresponded to DOT. For the calculation of WHO-DDD we used the WHO/ATC index in its 2016 version (www.whocc.no). For drugs without a WHO/ATC dose definition (for the relevant indication) we considered WHO-DDD to be identical to RDD. To compute the adapted guideline RDD we used the most recent (2015) version of RDD definitions published by a German hospital antibiotic use surveillance network (www. antiinfektiva-surveillance.de) ( Table S1 ). These RDD definitions have been used as an alternative to WHO/DDD for surveillance within the network but not as dosing recommendations or guidance. Prescribed doses of antibacterial drugs were converted into WHO-DDD and RDD by dividing the total amount of a substance (g) per patient per day by the two alternatively defined daily doses (g).
Statistical analysis
The proportions of PDD exactly matching (95%-105%) WHO-DDD and RDD, respectively, were computed. The matching rates of WHO-DDD/PDD and RDD/PDD were compared with each other via a McNemar test with a P value of ,0.05 indicating a significant difference between the matching rates. Pooled daily dose matching rates were computed for the entire patient population as well as for subgroups according to renal function, indication, D0 data only and antibacterial drug classes. WHO-DDD/PDD and RDD/PDD matching rates were also computed for each participating hospital and expressed as median and IQR. To evaluate the statistical significance of the difference in WHO-DDD/PDD and RDD/PDD matching rates across the hospital sample we performed a Wilcoxon signed-rank test.
As the exact matching rate only allows for a rough analysis of the overall equivalence of the dose definitions and the PDD, we also computed the degree of deviation in order to assess the discrepancy in drug use volume between truly prescribed PDD and drug use estimates. For that purpose we calculated pooled and median ratios of the numbers of WHO-DDD and RDD divided by PDD normalized to 100. The degrees of deviation from actual PDD were thus expressed as percentage overestimation or underestimation. These ratios were computed for the entire patient population as well as for subgroups according to renal function, indication, D0 data and different antibacterial drug classes. To evaluate the statistical significance of the difference of the deviations across the hospital sample we performed a Wilcoxon signed-rank test.
Ethical approval
The study was approved by the Ethics Committee of the University of Freiburg (No. 73/13) and by the institutional review boards or ethics committees of all participating centres, which waived the need for informed patient consent since the study was non-interventional and considered part of the hospitals' quality improvement processes.
Results
A total of 24 acute care hospitals of varying size participated in the study and reported the screening of 17274 inpatients of whom Fö rst et al. 4389 (25.4%) had any antimicrobial agent and 4226 (24.5%) had any systemic antibacterial drug prescribed on the day of the survey (D0). Patient characteristics and the primary indications for the prescribed drugs are given in Table 1 . The patients had a median age of 68 years. Most were admitted on normal medical service wards, and in most cases the indication for antibacterial drug prescription was for therapeutic purposes.
The total number of antibacterial PDD on D0 (5352) and the preceding 6 days (D-6-1: 15268) was 20620. The most commonly prescribed antibiotics were piperacillin/tazobactam (3007 PDD), ampicillin/sulbactam (2153 PDD), cefuroxime (2067 PDD), ciprofloxacin (1670 PDD) and trimethoprim/sulfamethoxazole (1425 PDD). Penicillins (6817 PDD) were given more frequently than cephalosporins (3600 PDD) and any other drug class.
Defined and prescribed daily dose matching
Overall, only 55% of the 20620 antibiotic PDD exactly matched the RDD. This rate was similar if only therapeutic indications were analysed (Table 2) , and was dependent on renal function. For the subgroup of patients with normal renal function the RDD/PDD matching rate was 61%, whereas for patients with impaired renal function it decreased to 42% (data not shown). RDD corresponded more frequently than WHO-DDD to PDD (overall, 55% versus 30%, P , 0.001), and this included the major drug classes b-lactams (including penicillins, cephalosporins and carbapenems) and macrolides/clindamycin where the differences were highly significant ( Table 2 ). The median rates (overall, 61% versus 32%) were similar to the pooled rates (Table S2) , and the difference remained significant (P , 0.01).
Unlike with RDD, the low rate of WHO-DDD corresponding to PDD was only marginally influenced by impaired renal function: this rate was 26% for patients with normal renal function, which was similar to the rates of 32% (slightly impaired renal function) and 26% (impaired renal function), respectively, which were still significantly lower than the RDD/PDD matching rates in the three subgroups [61% (normal renal function) versus 57% (slightly impaired renal function) versus 42% (impaired renal function)].
The differences in matching rates between WHO-DDD and RDD were large for b-lactams, and this included broad-, intermediateand narrow-spectrum agents ( Table 2 ). The differences were largest for penicillins both in the pooled analysis as well as across hospitals (Table 2 and Table S2 ). Pooled WHO-DDD/PDD matching rates for penicillins were ,10%, while the RDD/PDD matching rates were 61% (overall) and 63% after excluding prophylactic indications, respectively (Table 2 ). For the fluoroquinolones and aminoglycosides, in contrast, WHO-DDD/PDD matching rates were higher than RDD/PDD matching rates ( Table 2 and Table S2 ), indicating a possible need for further improved RDD dose definitions in specific areas.
Deviation of drug use volume estimates from actual prescription
Overall and for most drug classes including the most prevalent, the use of the current WHO-DDD definitions in our sample of hospitals would have resulted in an overestimation of drug use volumes, whereas using RDD definitions would give a relatively smaller underestimation (Table 3 and Figure 1 ). The overestimation by WHO-DDD in our sample would have been !28% overall compared with #14% underestimation if RDD had been used. As expected from the observed differences in dose matching rates, WHO-DDD largely overestimated penicillin use (Table 3) , and here in particular narrow-spectrum b-lactam use (pooled data, !251% for WHO-DDD versus #1% for RDD)-a result that was also expected based on the substantial differences between WHO-DDD and RDD in dose definitions for narrow-spectrum b-lactams that include penicillin derivatives only (Table S1 ). An exception to this finding was piperacillin/tazobactam, which has a high WHO-DDD (14 g) compared with the most frequently used dose of 12 g. In this case the use of WHO-DDD leads to a more pronounced underestimation of #22% compared with a smaller underestimation of #9% with RDD (data not shown), while the differences between WHO-DDD and RDD for the combined broad-spectrum b-lactam (including broad-spectrum cephalosporin and carbapenem) use estimates were small.
The general discrepancies appeared to be similar for the different service areas, but differed greatly for oral versus parenteral Validation of adapted daily dose definitions JAC antibiotics and for therapeutic versus prophylactic indication ( Figure 1 ): WHO-DDD typically overestimated parenteral drugs (!37%) and therapeutic drugs (!36%), while RDD underestimated oral drugs (#21%) and prophylactic drugs (#38%) but much less so parenteral drugs (#10%) and therapeutic drugs (#9%). Figure 2 depicts the overall deviation from PDD for WHO-DDD and RDD, respectively, in each participating hospital. The median overestimation using WHO-DDD was !32% (IQR 27%-41%), a rate slightly higher than the pooled !28%. The median deviation of RDD from PDD was #10% (IQR #15% to #7%) and slightly smaller than the pooled degree of deviation of #14%. There were similar patterns of discrepancies across the hospital sample for the different drug classes (Table S3 ). The proportion of penicillin PDD in each participating hospital showed a weak correlation (Pearson correlation coefficient: R 2 " 0.514) with the overall WHO-DDD/PDD discrepancy (Figure 2 insert) , suggesting that relatively high penicillin use among the hospitals tends to falsely classify these as overall high-use hospitals if WHO-DDD were used.
Discussion
The present analysis demonstrates that most of the proposed RDD are valid for measuring antimicrobial drug use in a typical German acute care hospital sample. Given the multicentre design of the present study, we can now be more confident that our RDD system for hospital antibiotic use surveillance remains a useful adjustment of the data when they are to be included in cross-sectional analyses and benchmarking reports. Although the sample was small and the participating hospitals cannot be regarded as truly representative for the German hospital sector, the study included hospitals of varying sizes and different geographical locations, with a typical distribution of patients across acute care services.
This study demonstrates that the use of recent versions of WHO-DDD for antibiotics in pharmacy-based surveillance programmes in the hospital setting may result in an overestimation of antibiotic consumption, above all regarding b-lactam use, and here particularly penicillin prescriptions. Adaptations in the dose definitions for typical hospital drugs according to hospital practice guideline recommendations, as proposed in the German system and shown here and by other investigators, 6, 8, 14 can reduce the discrepancies between drug use estimates and actual prescription, but are far from perfect. RDD gave values closer to real prescription rates, but still underestimated actual use by .10% overall and for most drug classes. Much of this inaccuracy can be traced to variability in renal function with dosage modifications, the often single or low doses of prophylactic antibiotics, and other factors. Part of it remains inevitable in pharmacy-based surveillance and can only be avoided by patient-level prescription data analysis. The distinct underestimation of fluoroquinolone and aminoglycoside use with RDD definitions clearly indicates the need to revise the RDD in our surveillance system and confirms the relevance of (whatever) dose definition validation studies in the environment for which surveillance and benchmarking are being planned and performed.
We found the largest discrepancies of all agents in the b-lactam class. The WHO-DDD/PDD matching rates were consistently low, with ,40% and sometimes even ,10% (penicillins), and the Fö rst et al. Validation of adapted daily dose definitions JAC deviation from actual prescribed doses was substantial with WHO-DDD, leading to a significant overestimation of overall use, particularly in hospitals or hospital areas where penicillins are the preferred agents. This finding agrees well with the assessment of the other two largest studies to date on this topic evaluating the measurement of antibiotic use via DOT 12 or hospital-adjusted DDD.
14 It was this potential bias due to uneven discrepancies across drug classes with previous and current WHO-DDD that led the German surveillance network to propose its RDD system for surveillance. Antibiotic stewardship programmes often encourage the use of penicillins rather than cephalosporins and fluoroquinolones, and we were uncertain whether using WHO-DDD in such a situation for benchmarking would classify hospitals following this policy falsely as general high antibiotic consumers based simply on this switch in policy. It is clear, however, that comparative analysis and benchmarking in the field of hospital antibiotic use should not and cannot rely solely on estimates of pharmacy-based drug use, but needs to include qualitative analysis. 17 The discrepancies observed for the WHO-DDD are not new. They have been described in earlier studies, 4, 6, 11, 12, 14 but the system continues to be used in international comparisons, and the b-lactam bias has not been resolved. Several adaptations in the WHO-DDD dose definitions for antibacterial drugs have been realized in the past. The most recent change is the new defined daily dose for ampicillin/sulbactam of 6 g (ampicillin component) versus the previous 2 g. 18 This dose corresponds to the ampicillin/sulbactam RDD we use in our system and has been evaluated in the current study. This important dose definition change for ampicillin/ sulbactam was much awaited and has now become effective (beginning of 2017). Ampicillin/sulbactam, interestingly, was the second most prescribed antibacterial drug in the current survey.
Using the data from the present study, we calculate that this most recent change would increase the WHO-DDD/PDD matching rate for penicillins from 7% to 22%, for intermediate-spectrum b-lactams from 16% to 34%, and for all antibacterial drugs in the present sample from 30% to 35%, respectively, which we believe represents a major improvement. More dose adaptations for penicillins and other b-lactam agents, however, are needed to decrease the discrepancies between WHO-DDD and PDD further and make specific (hospital-adapted) RDD probably dispensable.
A limitation of the present study is that it was confined to German acute care hospitals. The data cannot be generalized to chronic care or to international settings. Recommended doses may differ for the same indication between different practice guidelines and between different countries. Thus, guidelinederived adaptations in dose definitions would need international revalidation prior to their general implementation. The recommended doses also may change over time, entailing regular reevaluation and validation of the dose definitions. Another limitation is the exclusion of paediatric departments for which we have no established RDD system although there is a need to evaluate (pharmacy-based) drug use densities.
In conclusion, the results of this multicentre study confirm that guideline-derived hospital-adapted and validated dose definitions are needed for a solid and reliable measurement of hospital antibacterial drug consumption via pharmacy-based dispensing data. The German RDD system used so far, obviously, shows smaller and less-biased deviations from actual prescriptions compared with the current WHO-DDD system. This is highly relevant for b-lactam antibiotics as the most prevalent antibacterial drug class. As long as official hospital adapted DDD are not available, the RDD could be used as a supplementary measure to the WHO-DDD for detailed Fö rst et al.
analysis of the antimicrobial use at least in settings where guideline recommendations are comparable to dose definitions used in our surveillance programme.
